George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDirecta Plus Regulatory News (DCTA)

Share Price Information for Directa Plus (DCTA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.70
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.60 (3.261%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 18.70
DCTA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New patent grants

23 May 2019 07:00

RNS Number : 9202Z
Directa Plus PLC
23 May 2019
 

23 May 2019

 

Directa Plus plc

("Directa Plus" or the "Company")

 

New patent grants

 

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene-based products for use in consumer and industrial markets, is pleased to announce that the Company has been granted two new patents, for the application of the Company's G+ graphene products.

 

Graphene enhanced golf balls

 

The first is an Italian patent for the use of the Company's G+ graphene in the manufacture of golf balls. The use of the G+ compounds in golf balls, can provide a series of beneficial features that offer opportunities to develop a new generation of golf ball, both for professional and amateur players.

 

Certain G+ compounds will be able to achieve particular qualities when added to golf balls.

 

G+ materials can be used to enhance the hard core of professional golf balls in order to increase the shot distance potential of the ball, without losing lateral control. In addition, G+ can be used in the amateur golf ball market, to guarantee swing and improved control.

 

Preparing Graphene Nanoplatelets

 

The second is a Chinese patent, covering Directa Plus' unique process for the manufacturing graphene nanoplatelets.

Directa Plus's unique exfoliation technology is chemical free, has an extremely high yield, and can be varied to produce graphene nanoplatelets with specific morphologies. This means that G+ products are safe for human health, can be tailor-made to meet customers' needs, and the high-yields create competitive prices.

Additionally, the unique characteristics of the G+ process, allow the Company to enter large supply chains, in turn overcoming important entry barriers into the market.

 

Commenting on the agreement, Giulio Cesareo, Founder and CEO of Directa Plus, said:

 

"I'm very pleased that we were able to secure two new patents. We continue to show how our G+ graphene nanoplatelets can enhance products in various categories, and it is vital that we secure the Intellectual Property rights needed to protect our unique technology in worldwide jurisdictions.

 

"Securing Intellectual Property rights for our technological innovations is a key part of our corporate strategy - across global jurisdictions. The Company's current suite of patents now includes 22 granted, and a further 22 pending approval."

 

"Using our G+ product in golf balls, for both the amateur and professional game is an exciting opportunity to enter a large sporting market. "

 

"Additionally, gaining legal recognition of the Company's proprietary, chemical-free graphene production process in China will allow us to enter into larger Chinese supply chains more easily and overcome these barriers in the future."

 

 

 

For further information please visit http://www.directa-plus.com/ or contact:

 

Directa Plus plc

+39 02 36714458

Giulio Cesareo, CEO

 

Marco Ferrari, CFO

 

 

 

Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)

+44 20 7894 7000

Rick Thompson, Philip Davies Will Goode (Corporate Finance)

 

Caspar Shand Kydd (Sales)

 

 

 

N+1 Singer (Joint Broker)

+44 20 7496 3069

Mark Taylor, Lauren Kettle

 

 

 

Tavistock (Financial PR and IR)

+44 20 7920 3150

Simon Hudson, Barnaby Hayward, Edward Lee

 

 

About Directa Plus

Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product) and textiles (based on our G+ products). In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products. All our products are hypoallergenic, non-toxic and sustainably produced.

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRASEEEEEFUSEFI
Date   Source Headline
15th Apr 20243:01 pmRNSNotification of major holdings
12th Apr 20247:00 amRNSGiPave® installed at Imola Circuit
25th Mar 20247:00 amRNSEUR 1,000,000 Loan Agreement Signed
22nd Mar 20247:00 amRNSCollaboration with UK-based Heathcoat Fabrics
26th Feb 20247:00 amRNSAcquisition of 49% minority interest in Setcar
31st Jan 20247:00 amRNSContract win with FORD Otosan
20th Dec 20237:00 amRNSAcquisition of groundbreaking technology
15th Dec 202311:44 amRNSExpansion of collaboration with Miguel Caballero
10th Nov 20237:00 amRNSChange of Nominated Adviser
27th Sep 20237:00 amRNSHalf-year Report
18th Sep 20237:00 amRNSStrategic collaboration with The SPECTRUM Group
8th Sep 20237:00 amRNSNotice of Interim Results
7th Sep 20237:00 amRNSSignificant contract secured with LIBERTY Galati
19th Jul 20237:00 amRNSProject tender awarded
29th Jun 20237:00 amRNSDirecta Plus receives two new Italian patents
22nd Jun 20237:00 amRNSNew concept for produced water decontamination
15th Jun 20235:40 pmRNSResult of AGM
8th Jun 20237:00 amRNSNew product launch
19th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
10th May 20237:00 amRNSFinal Results
9th May 20237:00 amRNSNew contract with customer Alfredo Grassi
27th Apr 20237:00 amRNSNotice of Results Presentations
20th Mar 20237:00 amRNSNew Patent Granted
27th Feb 20237:00 amRNSTrading Update and Notice of Results
21st Dec 20227:00 amRNSNew significant contract with Pigmentsolution
5th Dec 20222:05 pmRNSSecond Price Monitoring Extn
5th Dec 20222:00 pmRNSPrice Monitoring Extension
2nd Dec 20227:00 amRNSTrading Update
29th Nov 20227:00 amRNSGrant Award
21st Nov 20227:00 amRNSDirectorate Change
28th Oct 20227:00 amRNSFirst Commercial Contract in Latin America
21st Oct 20227:00 amRNSFirst Major Commercial Contract for Gipave
17th Oct 20227:00 amRNSBoar Changes
17th Oct 20227:00 amRNSBoard Changes
29th Sep 202211:05 amRNSSecond Price Monitoring Extn
29th Sep 202211:00 amRNSPrice Monitoring Extension
29th Sep 20227:00 amRNSHalf-year Report
1st Sep 20227:00 amRNSTrading Statement
30th Aug 20227:00 amRNSUS Patent Notice
4th Aug 20227:00 amRNSPartnership Extension and US Patent Award
19th Jul 20227:00 amRNSAgreement with REDA Energy for Grafysorber
5th Jul 20227:00 amRNSSupply Agreement
22nd Jun 20227:00 amRNSGrant of Italian Filtration Patent
17th Jun 20223:40 pmRNSResult of AGM
17th Jun 20227:00 amRNSAGM Statement
19th May 20227:00 amRNSPosting of Annual Report and Notice of AGM
5th May 20227:00 amRNSFinal Results
22nd Apr 20227:00 amRNSPartnership to Develop Automotive Fabrics
4th Apr 20227:00 amRNSUS EPA Authorises Grafysorber for Use in US
7th Mar 20227:00 amRNSOxfordshire Starts Second Trial of GiPave

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.